Drugs / GINAKIT Cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03294954 | Jan 2018 → Dec 2027 expected | neuroblastoma | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT02439788 | Aug 2017 → Sep 2019 | neuroblastoma | Baylor College of Medicine | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GINAKIT Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03294954 ↗ |
| Action | Deplete | “NKT cells can specifically kill these macrophages and slow the tumor growth.” NCT03294954 ↗ |
| Modality | Cell therapy | “Natural Killer T cells will be genetically engineered to express GD2-CAR to attack neuroblastoma cells” NCT02439788 ↗ |
| Route | Other | “GINAKIT cell infusion” NCT02439788 ↗ |